Glooko named health tech veteran Russ Johannesson as its new chief executive this month, adding that the diabetes data management company’s former CEO, Rick Altinger, is slated to become EVP of corporate development.
Johannesson previously served as the chief operating officer of Sharecare, a digital health and wellness platform. Before that he led sales, marketing and client management activities as chief client officer at OptumHealth.
“Digital health solutions have proven impact for people with chronic diseases like diabetes and Glooko is driving real results among the patients and providers who use it,” Johannesson said in prepared remarks. “I am thrilled to be a part of a company with such a strong team, mission and product.”
“I look forward to getting back into a more hands-on role and working with Russ and the board to continue driving Glooko to its full potential,” Altinger added.
Earlier this year, the FDA approved Glooko’s mobile insulin dosing system, which is designed to titrate long-acting insulin for people with Type II diabetes.
The company’s system accesses blood glucose data directly from the user’s glucose meter so that the user doesn’t have to manually enter their fasting glucose values. Then, it analyzes those levels to recommend insulin dose adjustments based on a healthcare provider’s treatment plan and published clinical guidelines.
Glytec appoints chief operating exec
Glytec appointed Ed Furlong as chief operating officer last month, pointing towards an effort to scale its commercial operations.
“We are thrilled to welcome Ed Furlong to our executive team,” Glytec’s president & CEO, Bob Leonard, said. “Ed’s background in helping companies expand and diversify while sustaining strong financial health is ideally suited to our strategic imperatives, especially at this crucial juncture when demand for our products and services is increasing exponentially.”
“It is very exciting for me to join Glytec on the heels of a record year where software subscriptions grew by 70%,” Furlong said in a statement. “I am deeply impressed by the company’s track record of demonstrating both substantive cost savings as well as dramatic improvements in patient outcomes.”
Read more
Nemaura Medical names chief biz officer
In preparing for a commercial launch of its wireless, non-invasive glucose monitor, Nemaura Medical (NSDQ:NMRD) promoted Bashir Timol, who previously served as director of strategy & corporate development, to chief business officer.
“Bashir has brought significant business expertise to Nemaura Medical since our inception. As our chief business officer, he can provide critical leadership as the commercialization of sugarBeat draws closer,” CEO Faz Chowdhury said in a statement.
Read more
Pneuma Respiratory hires ex-Boehringer Ingelheim exec as president, CMO; names CFO
Pneuma Respiratory made two major hires over the last month, appointing an ex-Boehringer Ingelheim executive, Dr. Steven Kesten, as president & CMO, as well as naming former Wall Street banker Rich Gimigliano as chief financial exec.
“I am extremely excited about Pneuma’s innovative approach to improving the effectiveness of therapeutic agents that will help to address continuing issues in medication delivery in a large population of patients who continue to suffer from asthma and COPD. I believe that Pneuma’s inhaler technology can positively influence the large socioeconomic impact of obstructive lung disease,” Kesten said in a statement.
“I am extremely excited and honored to join Pneuma Respiratory. The company has assembled a strong operating and advisory team and I look forward to working with them as we build the business and explore the public markets,” Gimigliano added.
Read more
Natera hires chief medical officer
Natera (NSDQ:NTRA) this month named Dr. Paul Billings as chief medical officer, explaining that he will help lead the company’s reproductive health and oncology businesses.
“We are thrilled to have Dr. Billings join Natera,” CEO Matthew Rabinowitz said in prepared remarks. “Paul’s vision and expertise in applied genetics and personalized medicine are rare in the industry, and his experience working with CMS, FDA, commercial payors, academic institutions and patient advocacy groups will help us demonstrate clinical utility and improve patient access to our products and services.”
“I am excited to join Natera at this time of rapid innovation and growth for the company,” Billings added. “Natera has developed a leadership position in genetic testing, and I look forward to working with the medical communities in reproductive health and oncology to safely integrate these cutting-edge technologies into clinical practice.”
Read more
